688131 Stock Overview
Researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Shanghai Haoyuan Chemexpress Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.43 |
| 52 Week High | CN¥48.93 |
| 52 Week Low | CN¥17.86 |
| Beta | 0.29 |
| 11 Month Change | 6.80% |
| 3 Month Change | -13.67% |
| 1 Year Change | -51.20% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688131 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -3.4% | -4.4% | -3.0% |
| 1Y | -51.2% | -41.5% | -21.8% |
Return vs Industry: 688131 underperformed the CN Life Sciences industry which returned -41.5% over the past year.
Return vs Market: 688131 underperformed the CN Market which returned -21.8% over the past year.
Price Volatility
| 688131 volatility | |
|---|---|
| 688131 Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 688131 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688131's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 3,370 | Baofu Zheng | www.chemexpress.cn |
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. It offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.
Shanghai Haoyuan Chemexpress Co., Ltd. Fundamentals Summary
| 688131 fundamental statistics | |
|---|---|
| Market cap | CN¥4.30b |
| Earnings (TTM) | CN¥97.97m |
| Revenue (TTM) | CN¥1.97b |
43.2x
P/E Ratio2.2x
P/S RatioIs 688131 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688131 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.97b |
| Cost of Revenue | CN¥1.20b |
| Gross Profit | CN¥762.15m |
| Other Expenses | CN¥664.18m |
| Earnings | CN¥97.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 38.76% |
| Net Profit Margin | 4.98% |
| Debt/Equity Ratio | 36.6% |
How did 688131 perform over the long term?
See historical performance and comparison